ES2934138T3 - Uso de un polipéptido para efectuar la señalización inmunitaria y/o afectar la función de la barrera intestinal y/o modular el estado metabólico - Google Patents

Uso de un polipéptido para efectuar la señalización inmunitaria y/o afectar la función de la barrera intestinal y/o modular el estado metabólico Download PDF

Info

Publication number
ES2934138T3
ES2934138T3 ES16724321T ES16724321T ES2934138T3 ES 2934138 T3 ES2934138 T3 ES 2934138T3 ES 16724321 T ES16724321 T ES 16724321T ES 16724321 T ES16724321 T ES 16724321T ES 2934138 T3 ES2934138 T3 ES 2934138T3
Authority
ES
Spain
Prior art keywords
polypeptide
acid sequence
amino acid
seq
taught
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16724321T
Other languages
English (en)
Spanish (es)
Inventor
Clara Belzer
Vos Willem Meindert De
Patrice Daniel Cani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Wageningen Universiteit
Original Assignee
Universite Catholique de Louvain UCL
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL, Wageningen Universiteit filed Critical Universite Catholique de Louvain UCL
Application granted granted Critical
Publication of ES2934138T3 publication Critical patent/ES2934138T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES16724321T 2015-05-06 2016-05-04 Uso de un polipéptido para efectuar la señalización inmunitaria y/o afectar la función de la barrera intestinal y/o modular el estado metabólico Active ES2934138T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (1)

Publication Number Publication Date
ES2934138T3 true ES2934138T3 (es) 2023-02-17

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16724321T Active ES2934138T3 (es) 2015-05-06 2016-05-04 Uso de un polipéptido para efectuar la señalización inmunitaria y/o afectar la función de la barrera intestinal y/o modular el estado metabólico

Country Status (14)

Country Link
US (2) US10738089B2 (https=)
EP (1) EP3292135B1 (https=)
JP (1) JP6894382B2 (https=)
KR (1) KR102736980B1 (https=)
CN (1) CN107980043B (https=)
AU (2) AU2016257315A1 (https=)
DK (1) DK3292135T3 (https=)
EA (1) EA201700507A1 (https=)
ES (1) ES2934138T3 (https=)
HK (1) HK1252412A1 (https=)
IL (1) IL255405B (https=)
MX (1) MX390092B (https=)
PL (1) PL3292135T3 (https=)
WO (1) WO2016177797A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
DK3292135T3 (da) 2015-05-06 2022-10-31 Univ Wageningen Anvendelse af et polypeptid til at fremkalde immunsignalering og/eller påvirke tarmbarrierefunktion og/eller modulere metabolsk status
KR102569754B1 (ko) * 2015-09-10 2023-08-23 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 살균된 아커만시아의 용도
EP3790889A4 (en) * 2017-03-07 2022-06-08 Psomagen, Inc. DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS TARGETING TOLL-LIKE RECEPTORS AND METHODS THEREOF
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
WO2020226438A1 (ko) * 2019-05-07 2020-11-12 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
WO2021060945A1 (ko) * 2019-09-25 2021-04-01 ㈜헬스바이옴 암 치료를 위한 절대혐기성 인체 장내미생물 및 이의 용도
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
EP4087859A4 (en) * 2020-01-10 2024-02-14 National Taipei University of Technology PEPTIDE INTERACTING WITH THE TOLL-LIKE RECEPTOR 2 AND COMPOSITION THEREOF
CN115666627A (zh) * 2020-03-25 2023-01-31 韩国生命工学研究院 源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
AU2021299904A1 (en) * 2020-07-01 2023-01-19 Compagnie Gervais Danone Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
KR102911194B1 (ko) * 2020-11-05 2026-01-13 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN115364198A (zh) * 2022-08-23 2022-11-22 广州康泽医疗科技有限公司 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用
CN116059254B (zh) * 2023-02-27 2025-04-18 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用
KR102835266B1 (ko) 2023-09-11 2025-07-17 충남대학교산학협력단 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用
CN118063567B (zh) * 2024-03-03 2025-11-21 吉林大学 一种用于炎性肠病治疗的重组蛋白的制备与应用
CN119874827B (zh) * 2025-03-27 2025-06-13 杭州康源食品科技有限公司 一种具有免疫调节作用的九肽及其制备和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
JP3932358B2 (ja) * 2001-02-28 2007-06-20 独立行政法人産業技術総合研究所 ブラディオン遺伝子導入ショウジョウバエ株
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5290177B2 (ja) 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
US10576110B2 (en) 2009-05-11 2020-03-03 Societe Des Produits Nestle S.A. Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
EP2630448B1 (en) 2010-10-20 2016-12-14 Philips Lighting Holding B.V. Disaggregation apparatus
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
DK3292135T3 (da) 2015-05-06 2022-10-31 Univ Wageningen Anvendelse af et polypeptid til at fremkalde immunsignalering og/eller påvirke tarmbarrierefunktion og/eller modulere metabolsk status
KR102569754B1 (ko) 2015-09-10 2023-08-23 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 살균된 아커만시아의 용도
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Also Published As

Publication number Publication date
PL3292135T3 (pl) 2023-01-02
JP6894382B2 (ja) 2021-06-30
US11466057B2 (en) 2022-10-11
CN107980043B (zh) 2021-09-24
NZ737765A (en) 2024-08-30
JP2018515502A (ja) 2018-06-14
AU2020267210A1 (en) 2020-12-17
IL255405A0 (en) 2017-12-31
IL255405B (en) 2022-01-01
KR20180011130A (ko) 2018-01-31
EP3292135B1 (en) 2022-09-21
HK1252412A1 (zh) 2019-05-24
US20180265554A1 (en) 2018-09-20
DK3292135T3 (da) 2022-10-31
MX390092B (es) 2025-03-11
WO2016177797A1 (en) 2016-11-10
CN107980043A (zh) 2018-05-01
US10738089B2 (en) 2020-08-11
AU2020267210B2 (en) 2023-10-12
BR112017023751A2 (pt) 2018-07-31
KR102736980B1 (ko) 2024-12-02
EA201700507A1 (ru) 2018-05-31
US20210147489A1 (en) 2021-05-20
EP3292135A1 (en) 2018-03-14
AU2016257315A1 (en) 2017-11-23
CA2984985A1 (en) 2016-11-10
MX2017014111A (es) 2018-02-26

Similar Documents

Publication Publication Date Title
ES2934138T3 (es) Uso de un polipéptido para efectuar la señalización inmunitaria y/o afectar la función de la barrera intestinal y/o modular el estado metabólico
JP2018515502A5 (https=)
CN109415683B (zh) 新细菌物种
Levit et al. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health
EP3048905A2 (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
US20230265131A1 (en) Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
Jain et al. Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures
Zhu et al. Identification of γ-glutamyl-selenomethionine as the principal selenium metabolite in a selenium-enriched probiotic, Bifidobacterium longum, by two-dimensional HPLC-ICP MS and HPLC-ESI Orbitrap MS
BR112021002917A2 (pt) composições compreendendo cepas bacterianas
CN101608172A (zh) 一种用于减肥降脂的转化体及其制备方法
US10413588B2 (en) Probiotic function of human intelectin
JP6629955B2 (ja) 減量脂質低下のための形質転換体およびその構築方法、並びにその応用
CA2984985C (en) Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
KR20180013981A (ko) 우유 효소 처리물, 그 제조 방법, 조성물 및 제품
CN105255800A (zh) 一种重组乳酸菌及其应用
BR112017023751B1 (pt) Uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular
CN105296408A (zh) 一种新型抗i型糖尿病的重组乳酸菌及其应用
EA040421B1 (ru) Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
BR102020018367A2 (pt) Processo de obtenção de peptídeos antitumorais a partir de leite de jumenta hidrolisado
BR112018070962B1 (pt) Composição compreendendo uma cepa de akkermansia glycaniphilus isolada e uso da mesma